Dashboard
Manage Tickers

UNCYUnicycive Therapeutics, Inc.

Nasdaq unicycive.com


$ 0.40 $ -0.03 (-7.75 %)    

Monday, 05-Aug-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 437.96 $ 10.96 (2.57 %)
DIA $ 386.91 $ 0.72 (0.19 %)
SPY $ 518.58 $ 5.36 (1.04 %)
TLT $ 98.76 $ -1.18 (-1.18 %)
GLD $ 222.59 $ 2.29 (1.04 %)
$ 0.4336
$ 0.39
$ 0.40 x 100
$ 0.40 x 100
$ 0.39 - $ 0.41
$ 0.34 - $ 1.82
1,641,125
na
16.31M
$ -2.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-16-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-11-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

unicycive-therapeutics-shares-are-trading-higher-after-the-united-states-patent-and-trademark-office-granted-the-company-a-patent-on-uni-494-to-treat-acute-kidney-injury
Unicycive Therapeutics shares are trading ...
07/17/2024 11:06:02

unicycive-secures-patent-for-kidney-disease-treatment-uni-494-valid-until-2040
Unicycive Secures Patent for Kidney Diseas...
07/17/2024 11:05:17

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidne...

hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target
HC Wainwright & Co. Reiterates Buy on Unic...
07/10/2024 17:28:20

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

unicycive-therapeutics-announces-initial-patient-satisfaction-findings-from-pivotal-clinical-trial-of-oxylanthanum-carbonate-olc---company-says-patients-preferred-olc-more-than-4-to-1-over-prior-phosphate-binder-therapy
Unicycive Therapeutics Announces Initial P...
07/10/2024 11:07:41

greenbrier-fortress-biotech-and-3-stocks-to-watch-heading-into-monday
Greenbrier, Fortress Biotech And 3 Stocks ...
07/08/2024 07:10:02

unicycive-therapeutics-inc-files-for-resale-of-up-to-50m-shares-by-the-selling-stockholders
Unicycive Therapeutics Inc Files For Resal...
07/05/2024 20:03:31

- SEC Filing

unicycive-therapeutics-joins-russell-microcap-index
Unicycive Therapeutics Joins Russell Micro...
07/01/2024 11:10:16

Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidne...

hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target
HC Wainwright & Co. Reiterates Buy on Unic...
06/25/2024 16:12:08

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

unicycive-therapeutics-announced-results-from-the-oxylanthanum-carbonate-uni-olc-201-pivotal-trial-established-favorable-tolerability-and-safety-and-new-drug-application-submission-anticipated-in-q3-2024
Unicycive Therapeutics Announced Results F...
06/25/2024 11:32:33

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
06/11/2024 20:31:35

benchmark-reiterates-speculative-buy-on-unicycive-therapeutics-maintains-3-price-target
Benchmark Reiterates Speculative Buy on Un...
06/03/2024 15:59:32

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...

benchmark-reiterates-speculative-buy-on-unicycive-therapeutics-maintains-3-price-target
Benchmark Reiterates Speculative Buy on Un...
05/31/2024 15:09:54

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...

hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target
HC Wainwright & Co. Reiterates Buy on Unic...
05/29/2024 10:53:16

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/28/2024 20:31:18

unicycive-showcases-data-on-kidney-disease-therapies-at-european-renal-congress
Unicycive Showcases Data on Kidney Disease...
05/28/2024 11:09:41

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Associ...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
05/22/2024 20:31:33

unicycive-therapeutics-announced-that-two-posters-related-to-its-lead-product-candidate-oxylanthanum-carbonate-were-presented-at-the-national-kidney-foundation-spring-clinical-meeting
Unicycive Therapeutics Announced That Two ...
05/15/2024 11:08:41

hc-wainwright--co-reiterates-buy-on-unicycive-therapeutics-maintains-45-price-target
HC Wainwright & Co. Reiterates Buy on Unic...
05/14/2024 16:03:20

HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...

unicycive-therapeutics-q1-2024-gaap-eps-061-misses-015-estimate
Unicycive Therapeutics Q1 2024 GAAP EPS $(...
05/13/2024 20:38:21

Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate...

benchmark-reiterates-speculative-buy-on-unicycive-therapeutics-maintains-3-price-target
Benchmark Reiterates Speculative Buy on Un...
04/15/2024 15:00:32

Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 pric...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)